Tumor and Treatments Impact on Neurocognitive Functions and Quality of Life of Patients With OMS Grade II Glioma
- Conditions
- OMS Grade II Glioma
- Registration Number
- NCT01305122
- Lead Sponsor
- Centre Leon Berard
- Brief Summary
This is a multicenter prospective study:2 independant cohorts of patients with OMS grade II glioma will be followed during 5 years.
* cohort A: patients in first-line treatment (surgery, radiotherapy or chemotherapy)
* cohort B: patients with disease simple monitoring.
The primary endpoint is to evaluate the impact of tumor and treatments on neurocognitive functions and quality of life, using validate and standard tests.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- TERMINATED
- Sex
- All
- Target Recruitment
- 112
- OMS grade II glioma
- signed informed consent
- age >=18
- IK >=80%
- ability to read, write and undertand French
- glioma localized to brainstem
- other neurologic or psychiatric disease
- history of other malignancies, other than curatively treated in-situ carcinoma of the cervix or basal cell carcinoma of the skin, or any other curatively treated cancer with no sign of recurrence within 5 years prior to randomization
- neuroleptic concomitant treatment
- pregnant or lactating women
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method MoCA test 36 months
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (21)
CH Amiens-Picardie
🇫🇷Amiens, France
Institut de Cancérologie de l'Ouest
🇫🇷Angers, France
Hôpital Jean Minjoz
🇫🇷BESANCON Cedex, France
Hôpital Saint André
🇫🇷Bordeaux, France
Centre Georges François Leclerc
🇫🇷DIJON Cedex, France
Centre Oscar Lambret
🇫🇷LILLE Cedex, France
CHRU de Lille
🇫🇷LILLE Cedex, France
Hôpital d'instruction des armées Desgenettes
🇫🇷LYON Cedex 03, France
Centre Léon Bérard
🇫🇷LYON Cedex 08, France
Hôpital Guy de Chauliac
🇫🇷MONTPELLIER Cedex 5, France
Scroll for more (11 remaining)CH Amiens-Picardie🇫🇷Amiens, France